Other substances

Furosemide

A loop diuretic.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
3
 AI-suggested references
1
 Clinical trials

General information

Furosemide is a loop diuretic used for treatment of oedema resulting from a variety of conditions including congestive heart failure, renal failure, liver failure, or high pressure (DrugBank).


Furosemide on PubChem
Furosemide on Wikipedia


Marketed as

DIURAPID; DIURIN; DIURMESSEL; EUTENSIN; FRUMEX; FRUSENEX; FRUSOL; FURO-PUREN; FUROSEMIDE; LASIX; SEGURIL

 

Structure image - Furosemide

C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl

Supporting references

Link Tested on Impact factor Notes Publication date
Early short-course corticosteroids and furosemide combination to treat non-critically ill COVID-19 patients: An observational cohort study
Small molecule Cohort study 		Patients 4.84

Used as an adjunctive therapeutical in corticosteroid-treated patients. Significantly decreased primary outcome in the treated patients (efficacy was significant in the patient subgroup with elevated serum brain natriuretic peptide levels). Sample size: 26 + 93 control. Dosage: 80u202fmg/24u202fh for 4 days. Endpoints: Invasive mechanical ventilation requirement or 28-day mortality (primary).



 Sep/01/2020
Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study
Small molecule Cohort study 		Non-critically ill patients 6.07

A five-day treatment with a combination of colchicine, furosemide, prednisolone, acetylsalicylic acid, and a direct anti-Xa drug resulted in a significantly better outcome compared to the control. Sample size: 28 + 40 control. Dosage: 80 mg daily for 5 days. Main outcome: Composite of 28-day mortality, high-flow oxygen therapy requirement or mechanical ventilation requirement.

 Feb/09/2021

AI-suggested references

Link Publication date
Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide
Jun/30/2021
Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19
Jun/15/2020
Is Inhaled Furosemide a Potential Therapeutic for COVID-19?
Nov/24/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04588792 Furosemide as Supportive Therapy for COVID-19 Respiratory Failure Recruiting Phase 2|Phase 3 Apr/16/2021 Mar/01/2022
  • Alternative id - FaST-1
  • Interventions - Drug: Nebulized Furosemide|Drug: Nebulized Saline
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Alberta, Edmonton, Alberta, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|Kingston Health Sciences Center, Kingston, Ontario, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 640
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Improvement in pulmonary gas exchange|Requirement for mechanical ventilation|Mortality|Requirement for supplemental oxygen|Duration of ICU Stay|Length of hospitalization|Adverse events|Inhalation adverse events
Export (.csv)